Kincella, that is several hurdles down the track. They already have their patent for the Rhamnose Binding Protein(RBP), which is the part of the cancer cell the drug binds to. Now they have the patent to cover the extraction of the drug from the plant. That patent just locks up the technology tighter. The Orphan Drug status awarded by the FDA recently puts a tighter lock on it still. One of the few Australian companies to ever achieve this.
The biggest hurdle of all was the Phase 1/2a clinical trial. They proved the drug is safe to use on people and one patient went into long term remission. A feat no other biotech in Australia has achieved at that stage of developement against an advanced terminal cancer. A preview of the potency of the drug?
Looking good so far IMHO
Cheers
SBP
solbec pharmaceuticals limited
